Skip to main content
Equibles
KNSA $76.75 -1.39%
KNSA logo

KNSA · Kiniksa Pharmaceuticals International, plc

Track KNSA — free

Use KNSA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about KNSA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$76.75 -1.08 (-1.39%) At close · Aug 14
Market Cap
$11.98B
Shares
156.05M
All earnings calls

Earnings call · FY2026 Q1

Kiniksa Pharmaceuticals International, plc Q1 FY2026 Earnings Call

Kiniksa Pharmaceuticals International, plc Q1 FY2026 Earnings Call

Concluded Apr 28, 2026
Apr 28, 2026 0 turns
Period
FY2026 Q1
Runtime
—
Sources
2 artifacts
8-K 10-Q

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.

Forward guidance

1 guided metrics

Management's latest ranges and targets are included below.

Research coverage

2 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $214.27M +55.5% YoY
Diluted EPS $0.27 +145.5% YoY
Net income $22.59M +164.6% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

8-K earnings release Filed Apr 28, 2026 10-Q report Filed Apr 28, 2026

Forward guidance

From the 8-K filed Apr 28, 2026.

Metric Guided
ARCALYST net product revenue
2026
 $930M – $945M
Full-screen source Call document

Report a Problem

Category
Description
Email (optional, for follow-up)